Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475629 · ClinicalTrials.gov registry record · Phase 3
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
A Phase 3 study, sponsored by TaiMed Biologics.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT02475629: Completed Phase 3 study, sponsored by TaiMed Biologics.
NCT02475629 is a Phase 3 study that has completed, run by TaiMed Biologics. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02475629, a Phase 3 study, has completed, sponsored by TaiMed Biologics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
Primary Outcome
Proportion of participants (%) achieving a viral load reduction of at least 0.5 log from baseline (Day 7)
Interventions
- DRUG Optimized Background Regimen (OBR)
- BIOLOGICAL ibalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT02475629 record still lists
NCT02475629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Optimized Background Regimen (OBR) is the first listed.
NCT02475629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02475629 about?
NCT02475629 is a clinical study titled "Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV". This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
What is the current status of trial NCT02475629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2015-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02475629?
The interventions under investigation include: Optimized Background Regimen (OBR) (DRUG), ibalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02475629?
This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02475629's enrollment target sits among peer trials
40 1878th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia